Heidi Kay, Ph.D.

Dr. Heidi Kay is the Founder and CEO of Jericho Sciences. She brings more than 25 years of drug and assay research experience. As a faculty member at the University of South Florida (USF) in Tampa, she collaborated with the H. Lee Moffitt Cancer Center as the lead inventor of a novel class of drugs targeting STAT3 transcription proteins. This work resulted in several awarded patents and high-impact journal publications - including Nature Medicine - and over 2,500 citations of her published work to date. In 2009, she founded Jericho Sciences to pursue discoveries useful for improving current therapeutic strategies for treating immunodeficiency virus infections, including HIV-1. She has been the primary recipient of several nondilutive NIH SBIR grants for Jericho Sciences, resulting in newly awarded patents relating to novel treatments for HIV-1 infection. Based upon this work, NIH has selected Jericho Sciences as an NIH Showcase Company for the upcoming BIO International Convention in June 2022. Dr. Kay obtained her Ph.D. in Physical Chemistry at USF under the direction of the Distinguished Professor, Dr. Brian Stevens, best known for his work in Singlet Molecular Oxygen.